Daniel Elger

Daniel Elger has extensive work experience in the biotech and pharmaceutical industry. Daniel is currently the Chief Executive Officer at CABI, a position they have held since September 2020. Daniel is also a Non Executive Director at Conidia Bioscience since December 2020.

Before these roles, Elger held senior leadership positions at various companies. From 2015 to 2020, they worked at Summit Therapeutics where they were the Senior Vice President R&D and Chief Commercial Officer. At Summit Therapeutics, they were responsible for commercial, medical affairs, and business development functions.

Prior to that, they were the Chief Financial & Corporate Development Officer at Genkyotex S.A from 2014 to 2015, overseeing pipeline development planning, financing, and corporate development. From 2011 to 2014, they were the Chief Financial Officer at e-therapeutics PLC, where they led a £40m fundraising on AIM.

Elger also has experience at Antisoma as the VP of Marketing & Communications from 2002 to 2011. Daniel was a member of the Senior Management Team and played a key role in the development and approval of drugs for various types of cancer.

Earlier in their career, Elger held various positions at Huntsworth Health, Mosby-Wolfe, and INTERNATIONAL THOMSON PUBLISHING LIMITED, gaining experience in program management, development editing, and senior editing roles.

Overall, Daniel Elger has a diverse background in the biotech and pharmaceutical industry, with a focus on leadership, finance, and business development.

Daniel Elger completed their education with a PhD in Cancer Biology from the University of Oxford from 1991 to 1994. Prior to that, they obtained a BA in Medicine (Physiological Sciences) from the same university, studying from 1988 to 1991. Daniel attended Whitley Abbey Comprehensive School in Coventry from 1981 to 1988, but no degree or field of study is specified for this period.